Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.71 |
| ▸ | MAPT | P10636 | 8/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | TP53 | P04637 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2774527 | 0.86 | MAPT (0.74) | HSD17B10MAPTSMN1; SMN2GPBAR1HPGD | |
| SCHEMBL11894104 | 0.86 | POLB (0.77) | MAPTALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL27910275 | 0.85 | HSD17B10 (0.78) | HSD17B10MAPTSMN1; SMN2GPBAR1ALDH1A1 | |
| SCHEMBL13734519 | 0.85 | ALDH1A1 (0.62) | HSD17B10MAPTSMN1; SMN2GPBAR1HPGD | |
| SCHEMBL459354 | 0.84 | HSD17B10 (0.76) | HSD17B10MAPTGPBAR1HPGDALDH1A1 | |
| SCHEMBL32679558 | 0.84 | HSD17B10 (0.76) | HSD17B10MAPTSMN1; SMN2GPBAR1ALDH1A1 | |
| SCHEMBL10520547 | 0.84 | HSD17B10 (0.76) | HSD17B10MAPTSMN1; SMN2GPBAR1MEN1 | |
| SCHEMBL315858 | 0.84 | HSD17B10 (0.76) | HSD17B10MAPTSMN1; SMN2GPBAR1ALDH1A1 | |
| SCHEMBL30395456 | 0.84 | HSD17B10 (0.76) | HSD17B10MAPTGPBAR1HPGDALDH1A1 | |
| SCHEMBL5533828 | 0.83 | LMNA (0.74) | HSD17B10MAPTGPBAR1ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3679034-B1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | IMMUNIC AG (DE) | 2022-06-01 | — | — | EP | disclosed |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2022-04-05 | — | — | US | disclosed |
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2021-03-04 | — | — | US | disclosed |
| EP-2699566-B1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | IL-YANG PHARM CO LTD (KR) | 2017-02-22 | — | — | EP | disclosed |
| US-9132126-B2 | Phenyl-isoxazole derivatives and preparation process thereof | IL-YANG PHARM. CO., LTD. (KR) | 2015-09-15 | — | — | US | disclosed |
| EP-2699566-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | Il-Yang Pharm. Co., Ltd. (KR) | 2014-02-26 | — | — | EP | disclosed |
| US-20140031364-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | IL-YANG PHARM. CO., LTD. (KR) | 2014-01-30 | — | — | US | disclosed |
| WO-2012144752-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | IL-YANG PHARM. CO., LTD. (KR) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | HSD17B10 381/4885MAPT 4132/4885SMN1; SMN2 4231/4885 |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | HSD17B10 381/4885MAPT 4132/4885SMN1; SMN2 4231/4885 |
| US-20140031364-A1 | PHENYL-ISOXAZOL DERIVATIVES AND PREPARATION PROCESS THEREOF | PIR, ALPL, PIGS | HSD17B10 3731/4885MAPT 620/4885SMN1; SMN2 3568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.